Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:625305rdf:typepubmed:Citationlld:pubmed
pubmed-article:625305lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C0024554lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C0010802lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:625305lifeskim:mentionsumls-concept:C0700015lld:lifeskim
pubmed-article:625305pubmed:issue3lld:pubmed
pubmed-article:625305pubmed:dateCreated1978-4-17lld:pubmed
pubmed-article:625305pubmed:abstractTextThe cytogenetic effects of Myleran were examined in bone-marrow cells from male mice. To study the dose--response relationship the male mice were injected with 5, 10, 20 or 40 mg of Myleran/kg. Bone-marrow samples were prepared 24 h later. The time response was investigated by examining bone-marrow samples 1, 2, 4 or 10 days after i.p. injection of 40 mg of Myleran. Most of the structural aberrations were of the chromatid type and the dose--response relationship was linear. The chromatid and chromosomal aberrations were maximal at 2 days and decreased sharply after longer intervals of time.lld:pubmed
pubmed-article:625305pubmed:languageenglld:pubmed
pubmed-article:625305pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:625305pubmed:citationSubsetIMlld:pubmed
pubmed-article:625305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:625305pubmed:statusMEDLINElld:pubmed
pubmed-article:625305pubmed:monthJanlld:pubmed
pubmed-article:625305pubmed:issn0027-5107lld:pubmed
pubmed-article:625305pubmed:authorpubmed-author:LéonardAAlld:pubmed
pubmed-article:625305pubmed:authorpubmed-author:LéonardE DEDlld:pubmed
pubmed-article:625305pubmed:issnTypePrintlld:pubmed
pubmed-article:625305pubmed:volume56lld:pubmed
pubmed-article:625305pubmed:ownerNLMlld:pubmed
pubmed-article:625305pubmed:authorsCompleteYlld:pubmed
pubmed-article:625305pubmed:pagination329-33lld:pubmed
pubmed-article:625305pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-A...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-M...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-C...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-M...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-B...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-B...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-C...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-T...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-D...lld:pubmed
pubmed-article:625305pubmed:meshHeadingpubmed-meshheading:625305-M...lld:pubmed
pubmed-article:625305pubmed:year1978lld:pubmed
pubmed-article:625305pubmed:articleTitleCytogenetic effects of myleran in vivo on bone-marrow cells from male mice.lld:pubmed
pubmed-article:625305pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:625305pubmed:publicationTypeIn Vitrolld:pubmed